^
Association details:
| Biomarker: | KRAS G12C + PD-L1 underexpression + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploratory biomarker analyses from a phase 2 trial evaluating sotorasib in patients with pretreated KRASG12C-mutated non-small cell lung cancer (CodeBreaK 100)
Published date:
08/05/2021
Excerpt:
In these exploratory analyses of the registrational phase 2 CodeBreaK 100 trial, the clinical benefit of sotorasib in KRASG12C-mutated NSCLC was observed across a range of patient subgroups including patients with low PD-L1 expression level and those with co-occurring STK11 mutation.
Trial ID:
